Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Hub and spoke dispensing between separate pharmacy businesses to begin in October

Numark welcomes hub and spoke change, but calls for clear economic model

The H Human Medicines Regulations amendments will come into force on 1 October 2025.

Image credit: Getty Images

Community Pharmacy England (CPE) has confirmed that the government has laid amendments to the Human Medicines Regulations 2012 (HMR) in Parliament, marking a crucial step towards enabling hub and spoke dispensing between separate community pharmacy businesses.

The Human Medicines (Amendments Relating to Hub and Spoke Dispensing etc.) Regulations 2025 are set to come into force on 1 October 2025.


However, as pharmacies are required to notify their Integrated Care Board (ICB) at least 28 days before commencing hub and spoke dispensing for NHS prescriptions, the earliest possible implementation date would be 29 October 2025.

Currently, hub and spoke dispensing is only permitted between community pharmacies owned by the same legal entity (the same retail pharmacy business).

These new regulatory changes will, for the first time, allow independent pharmacies (different retail pharmacy owners) to carry out hub and spoke dispensing under Model 1 – where medicines are assembled by the hub and returned to the spoke pharmacy for supply to the patient (patient – spoke – hub – spoke – patient).

Model 2, where the hub pharmacy supplies medicines directly to the patient (patient – spoke – hub – patient), will not be introduced due to patient safety and regulatory concerns.

Harry McQuillan, chairman of Numark, described the government's announcement as “a welcome move toward enabling greater flexibility and efficiency in community pharmacy.”

He noted that while the operational model is now broadly understood, the economic model remains unclear, and “that will be critical in determining how this change will truly benefit the sector.”

"At Numark, we are actively exploring how this legislation could open up opportunities for our members.”

“We are working to evaluate solutions that could support them to access the benefits of scale, while maintaining their local presence and patient relationships.”

"As always, the detail will be key,” he added.

He stressed that it is essential for the regulatory and economic frameworks to align in order to offer genuine, practical advantages to the sector.

Meanwhile, the CPE continues discussion with the Department of Health and Social Care (DHSC) for further amendments to the NHS (Pharmaceutical and Local Pharmaceutical Services) Regulations (PLPS).

These will enable NHS spoke pharmacies to subcontract part of the NHS Essential Dispensing Service to the hub.

Key points of the HMR amendments include:

  • Written agreements must be in place between the hub and spoke pharmacies, clearly outlining their respective responsibilities.
  • The dispensed medicine must be labelled with the spoke’s name and address, and the date on which the hub assembled or part assembled the medicine, along with all the usual information required on a dispensing label.
  • Patient data sharing between the hub and spoke is permitted without the patient’s explicit consent through an information gateway, provided appropriate notices are displayed at both hub and spoke sites to maintain the confidentiality of the patient data.

CPE said that they will be providing a briefing on Hub and Spoke dispensing and the new HMR amendments in the coming weeks.

More For You

Chemotherapy-free leukaemia treatment

The trial found that a combination of two cancer drugs, ibrutinib and venetoclax, could perform better than chemotherapy among patients with chronic lymphocytic leukaemia.

iStock

Chemotherapy-free leukaemia treatment shows promise during trial

In a breakthrough in leukaemia research, scientists in the UK have tested a chemotherapy-free approach, involving a combination of targeted drugs, which may offer better outcomes.

The new treatment could radically change the way chronic lymphocytic leukaemia (CLL), the most common form of leukaemia in adults, is treated.

Keep ReadingShow less
Wales ranked worst for second-trimester abortion access in the UK

Each year about 175 women travel from Wales to England for care

Wales ranked worst for second-trimester abortion access in the UK

A leading healthcare charity has revealed that Wales is the worst part of the United Kingdom for allowing surgical abortions for women.

Surgical abortion is the process removing pregnancy from the womb by inducing local anaesthesia, conscious sedation or general anaesthesia.

Keep ReadingShow less
The fund offers £150 per eligible child - for up to three children per household.

The fund offers £150 per eligible child - for up to three children per household.

Charity reopens funding to ease back to school financial pressures for community pharmacists

Community pharmacists struggling with the costs of their children going back to school can apply for funding from The Leverhulme Trade Charities Trust (LTCT)

The Trust is providing up to £100,000 of support to those working in a community pharmacy or are a registered pharmacist or pharmacy technician

Keep ReadingShow less
Germany's BioNTech to buy CureVac to boost cancer research

Both biotech companies have been working for years in the area of mRNA vaccines and treatments

Germany's BioNTech to buy CureVac to boost cancer research

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, bringing together two pharmaceutical firms specialised in mRNA technology with the goal of advancing cancer treatments.

BioNTech, which developed the first coronavirus vaccine to be approved in the West along with US pharmaceutical giant Pfizer, said the acquisition would "bring together complementary capabilities and leverage technologies".

Keep ReadingShow less
Amandeep Doll RPS  New Director of England

Amandeep Doll

RPS announces new director of England

Amandeep Doll has been named as the new director for England at the Royal Pharmaceutical Society (RPS).

The role of Director for England drives professional leadership for the pharmacy profession in England, and leads on national policy development and advocacy across England, in partnership with the English Pharmacy Board.

Keep ReadingShow less